Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
241-260 of 604 trials

Kidney Transplant: BIVV020 for Rejection Prevention and Treatment

We are studying BIVV020 to see if it can help prevent or treat antibody-mediated rejection in adults who have received a kidney transplant. This trial will assess its safety and how well it works compared to current treatments.

Transplant Rejection1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyInfectious DiseasesInternal MedicineOncology

Chronic Low Back Pain: Stem Cell Injection Study

We are investigating whether injecting stem cells into the spine can help reduce pain and improve function in people with chronic low back pain from degenerative disc disease. This trial is for those who haven't responded to traditional treatments.

Degenerative Disc Disease>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Venous Malformations: Enalapril Study

We are testing the medication enalapril in adults with painful venous malformations to see if it helps reduce pain and improve quality of life. We will also look at any changes in the size of the malformations.

Venous Malformation>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

ARDS Treatment: Recombinant Human Plasma Gelsolin

We are studying whether intravenous recombinant human plasma gelsolin is safe and may help patients with moderate-to-severe ARDS caused by pneumonia or infections. This trial compares it to a placebo alongside standard care.

Acute Respiratory Distress Syndrome (ARDS)≤3 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementInfectious DiseasesPulmonology

Takotsubo Syndrome: Beta-Blockers Study

We are investigating whether beta-blockers can help improve heart function in patients with Takotsubo Syndrome. This study will also look at various heart health measures and quality of life.

Takotsubo Syndrome1-2 yearsMonitoring phase (IV)6-10 visitsPartially RemoteCardiologyInternal Medicine

Rheumatoid Arthritis: FBL-MTX Injection Study

We are investigating a new injectable treatment for moderate-to-severe rheumatoid arthritis in patients who haven't used DMARDs or have had issues with oral methotrexate. The study will evaluate how well it works and its safety.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInternal MedicineRheumatology

Prurigo Nodularis: Barzolvolimab Study

We are testing a new medication, barzolvolimab, for people with prurigo nodularis to see if it helps reduce itching and improve skin lesions. The study will also look at the safety of this treatment and its effects on quality of life.

Prurigo Nodularis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Pneumococcal Vaccine Response: Age and HIV Impact

We are studying how age and HIV infection affect the immune response to pneumococcal vaccination. This research aims to improve vaccine effectiveness for different populations.

HIV Infection6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Severe Diffuse Cutaneous Systemic Sclerosis: Rapcabtagene Autoleucel vs. Rituximab

We are studying a new treatment to see if it works better than rituximab for people with severe diffuse cutaneous systemic sclerosis. The trial will also evaluate the safety of this new therapy.

Systemic Scleroderma1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Advanced Solid Tumors and Blood Cancer: Durvalumab and Tremelimumab Study

We are testing the safety and early effectiveness of Durvalumab alone and with Tremelimumab in children with advanced solid tumors and blood cancers. This study aims to find the best dosage and understand how these treatments work.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Brivaracetam for Childhood Absence Epilepsy

We are studying whether brivaracetam is effective and safe for children and young adults aged 2 to 25 with childhood or juvenile absence epilepsy. This trial aims to provide insights into its use as a standalone treatment.

Childhood Absence Epilepsy3-6 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Myopia in Children: Atropine Eyedrops Study

We are testing two concentrations of atropine eyedrops to see if they can slow the progression of myopia in children and teens aged 3 to under 18. The study will also look at safety and how vision affects daily life.

Myopia>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Psilocybin Therapy for Depression in Serious Illnesses

We are studying whether medium/high doses of psilocybin can help reduce depression and anxiety in patients with COPD, ALS, MS, or APD. This research aims to improve their quality of life and support their caregivers.

Chronic Respiratory and Neurological Disorders≤3 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePsychiatryPulmonology

Heart Transplant in Children: Comparing Custodiol and Custodiol-N

We are studying the safety of two organ preservation solutions during heart transplants in children. This research aims to see which solution better supports recovery and overall health after surgery.

Heart Transplantation in Children>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteCardiologyPediatrics

Interstitial Lung Disease: Rituximab and Mycophenolate Combination

We are studying a combination of rituximab and mycophenolate mofetil for patients with interstitial lung disease related to systemic sclerosis. The goal is to see if this treatment improves lung function and overall health compared to a placebo.

Lung Involvement in Systemic Sclerosis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsStandard MedicinesPulmonologyRheumatology

Acute Myeloid Leukemia: KO-539 Treatment Study

We are testing a new drug called KO-539 in patients with relapsed or refractory acute myeloid leukemia. The goal is to see if it is safe and effective for those with specific genetic mutations.

Relapsed Acute Myeloid Leukemia≤3 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

High-Risk Myelodysplastic Syndromes: Stem Cell Transplantation Study

We are evaluating a new treatment approach that combines hypomethylating therapy with stem cell transplantation for patients with high-risk myelodysplastic syndromes. The study aims to assess the feasibility and safety of this combined treatment.

Myelodysplastic SyndromeConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

Mucositis Prevention: Dexpanthenol Mouth Rinse

We are studying whether a new mouth rinse can help reduce mouth sores in patients receiving radiation therapy. The trial compares this rinse to a placebo to see if it improves comfort and quality of life.

Radiation-Induced Oral Mucositis>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesDermatologyOncologyOtolaryngology

Targeted Anti-Cancer Treatment: ProTarget Trial

We are studying how effective and safe targeted cancer drugs are for patients with advanced cancer and specific genetic markers. This research may help improve treatment options based on individual genetic profiles.

Cancer3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Non-Alcoholic Steatohepatitis: Namodenoson Study

We are testing a new oral medication, namodenoson, for individuals with Non-Alcoholic Steatohepatitis (NASH). The study aims to see if it improves liver health and to evaluate its safety.

Non-Alcoholic Steatohepatitis (NASH)6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine